Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.

Vega KJ, May R, Sureban SM, Lightfoot SA, Qu D, Reed A, Weygant N, Ramanujam R, Souza R, Madhoun M, Whorton J, Anant S, Meltzer SJ, Houchen CW.

J Gastroenterol Hepatol. 2012 Apr;27(4):773-80. doi: 10.1111/j.1440-1746.2011.06928.x.

2.

Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.

Mokrowiecka A, Veits L, Falkeis C, Musial J, Kordek R, Lochowski M, Kozak J, Wierzchniewska-Lawska A, Vieth M, Malecka-Panas E.

Pathol Res Pract. 2017 Mar;213(3):205-209. doi: 10.1016/j.prp.2016.12.018. Epub 2016 Dec 30.

PMID:
28216140
3.

Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.

Bobryshev YV, Freeman AK, Botelho NK, Tran D, Levert-Mignon AJ, Lord RV.

Dis Esophagus. 2010 Sep;23(7):580-9. doi: 10.1111/j.1442-2050.2010.01061.x. Epub 2010 Apr 29.

PMID:
20459440
4.

Acid, bile, and CDX: the ABCs of making Barrett's metaplasia.

Souza RF, Krishnan K, Spechler SJ.

Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G211-8. doi: 10.1152/ajpgi.90250.2008. Epub 2008 Jun 12. Review.

5.

High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.

Fisher OM, Levert-Mignon AJ, Lord SJ, Botelho NK, Freeman AK, Thomas ML, Falkenback D, Wettstein A, Whiteman DC, Bobryshev YV, Lord RV.

Ann Surg Oncol. 2015 Jul;22(7):2431-8. doi: 10.1245/s10434-014-4155-y. Epub 2014 Oct 28.

6.

Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.

Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS, Bernstein H.

Am J Gastroenterol. 2009 Feb;104(2):302-9. doi: 10.1038/ajg.2008.85. Epub 2009 Jan 27.

7.

DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.

Whorton J, Sureban SM, May R, Qu D, Lightfoot SA, Madhoun M, Johnson M, Tierney WM, Maple JT, Vega KJ, Houchen CW.

Dig Dis Sci. 2015 Feb;60(2):509-13. doi: 10.1007/s10620-014-3347-4. Epub 2014 Oct 5.

PMID:
25283374
8.

Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.

Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer DG, Agarwal R, Abraham JM, Meltzer SJ.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7. doi: 10.1158/1055-9965.EPI-07-0407.

9.

Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.

Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, Tyagi S, Hayward NK, Whiteman DC; Australian Cancer Study.; Study of Digestive Health..

PLoS One. 2011;6(7):e22513. doi: 10.1371/journal.pone.0022513. Epub 2011 Jul 28.

10.

Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders.

Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD.

Hum Pathol. 2001 Nov;32(11):1157-65.

PMID:
11727253
11.

Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.

Kauttu T, Mustonen H, Vainionpää S, Krogerus L, Ilonen I, Räsänen J, Salo J, Puolakkainen P.

Clin Transl Oncol. 2017 Jan;19(1):58-66. doi: 10.1007/s12094-016-1503-3. Epub 2016 Mar 30.

PMID:
27026568
12.

LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus?

von Rahden BH, Kircher S, Lazariotou M, Reiber C, Stuermer L, Otto C, Germer CT, Grimm M.

J Exp Clin Cancer Res. 2011 Feb 23;30:23. doi: 10.1186/1756-9966-30-23.

13.

Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma.

Becker L, Huang Q, Mashimo H.

Dis Esophagus. 2010 Feb;23(2):168-74. doi: 10.1111/j.1442-2050.2009.00979.x. Epub 2009 Jun 22.

PMID:
19549212
14.

Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively.

May R, Sureban SM, Hoang N, Riehl TE, Lightfoot SA, Ramanujam R, Wyche JH, Anant S, Houchen CW.

Stem Cells. 2009 Oct;27(10):2571-9. doi: 10.1002/stem.193.

16.

Immunolocalization of DCAMKL-1, a putative intestinal stem cell marker, in normal colonic tissue.

Gagliardi G, Moroz K, Bellows CF.

Pathol Res Pract. 2012 Aug 15;208(8):475-9. doi: 10.1016/j.prp.2012.05.015. Epub 2012 Jun 30.

PMID:
22749579
17.

Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.

Darlavoix T, Seelentag W, Yan P, Bachmann A, Bosman FT.

Virchows Arch. 2009 Jun;454(6):629-37. doi: 10.1007/s00428-009-0769-z. Epub 2009 Apr 25.

PMID:
19396460
18.

Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.

Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, Uetake H, Kawakami K, Park JM, Salonga D, Peters JH, DeMeester TR, Hölscher AH, Danenberg PV.

J Gastrointest Surg. 2001 Mar-Apr;5(2):174-81; discussion 182.

PMID:
11331481
19.

Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.

Brabender J, Lord RV, Wickramasinghe K, Metzger R, Schneider PM, Park JM, Hölscher AH, DeMeester TR, Danenberg KD, Danenberg PV.

J Gastrointest Surg. 2002 May-Jun;6(3):359-67.

PMID:
12022988
20.

Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.

Kazeminezhad B, Mirafsharieh SA, Dinyari K, Azizi D, Ebrahimi A.

Turk J Gastroenterol. 2014 Jun;25(3):253-6. doi: 10.5152/tjg.2014.5454.

Supplemental Content

Support Center